U.S. President Donald Trump has signed an executive order on Thursday that could potentially reclassify marijuana to a less severe drug category, paving the way for enhanced medical research opportunities. This move represents a significant departure from current federal drug policies and aligns more closely with actions taken by numerous individual states.
Under the proposed reclassification, marijuana would no longer be classified as a Schedule I drug alongside substances like heroin and LSD. Instead, it would be categorized as a Schedule III substance, similar to ketamine and certain anabolic steroids. While this adjustment would not legalize recreational marijuana use nationwide, it could lead to changes in how the drug is regulated and potentially alleviate the heavy tax burden on the cannabis industry.
President Trump noted that he received overwhelming support for this action, particularly from individuals advocating for improved access to medical marijuana to alleviate suffering. In contrast to his predecessor, Joe Biden, Trump’s administration has taken steps towards reclassifying marijuana, with the potential to expedite the process within the Drug Enforcement Administration.
Although some Republicans have voiced opposition to reclassification, citing concerns about maintaining current standards, the move could have a profound impact on the evolving landscape of marijuana regulation. Despite the legalization of marijuana for recreational and medical purposes in many states, conflicting federal laws have left individuals vulnerable to federal prosecution.
Public opinion, as reflected in polling data from Gallup, indicates a growing acceptance of marijuana legalization in the U.S. Trump’s executive order also emphasizes the importance of expanding research and accessibility to CBD, a hemp-derived product. Additionally, a new Medicare initiative aims to provide legal hemp-derived CBD to older adults at no cost, subject to medical recommendation.
However, resistance to reclassification persists among some Republican senators, who argue that marijuana remains a hazardous substance with potential negative impacts on health and safety. They caution against undermining existing efforts and express concerns about the influence of foreign markets, such as China, in the cannabis industry.
While Trump has not committed to decriminalizing marijuana, his administration has prioritized combating other drugs, particularly fentanyl, through various executive actions. These initiatives underscore the administration’s focus on addressing drug-related challenges and enhancing public safety.
Overall, the executive order signed by President Trump marks a significant step towards potential reforms in marijuana regulation and research, reflecting evolving attitudes towards drug policy in the United States.